Roxithromycin

Roxithromycin has been studied in 4 papers since 2018: none in people yet, 1 in animals, 1 in cells, 1 review; 1 in the past year. The research so far is in animals and cells. The newest paper, Jan 15, 2026: “Comparative efficacy of pharmacological agents on abdominal aortic aneurysm growth rate: a systematic review and network meta-analysis”.

Intervention

4 papers study it4 findingsUpdated

PubChemChEBIMeSH

See all 4 papers on roxithromycin

At a glance

The findings reach people, from one lab or study. 2 independent labs in 1 country; 1 trial, none about aging, 1 with no results posted.

None of its findings points the other way.

Cells, mice and humans: a single group. Worms or flies: nothing yet.
  • 2 independent labs in 1 country
  • 1 trial, none about aging, 1 with no results posted
  • Funders: K. C. Wong Education Foundation and 4 more
  • Animals1
  • Cells1
  • In silico1

What did studies of roxithromycin find?

4

Studies of roxithromycin measured 4 outcomes, among them abdominal aortic aneurysm growth rate, NOX4 and cellular senescence.

Abdominal aortic aneurysm growth rate

downin humans1

1 study
  1. Roxithromycin decreases abdominal aortic aneurysm growth rate in humans (Pooled randomized controlled trials) (SMD 0.39, 95% CrI -0.69 to -0.10 (as reported)).

    “Pooled RCT results showed roxithromycin significantly reduced AAA growth (SMD [95% CrI]: 0.39 [-0.69 to -0.10]).”

    ReviewPooled randomized controlled trialsabdominal aortan = 2,135

    Comparative efficacy of pharmacological agents on abdominal aortic aneurysm growth rate: a systematic review and network meta-analysis

    Frontiers in pharmacology

NOX4

downin mouse cells1

1 study
  1. Roxithromycin inhibits NOX4 in mouse cells.

    “NADPH oxidase 4 (NOX4), implicated in lung fibrosis and cell senescence, was shown to be inhibited by RXM treatments.”

    Cells

    Roxithromycin attenuates bleomycin-induced pulmonary fibrosis by targeting senescent cells

    Acta pharmacologica Sinica

More on NOX4

Cellular senescence

downin mice1

1 study
  1. Roxithromycin decreases cellular senescence in mice (bleomycin-induced model).

    “the senescent phenotype of lung tissues induced by BLM was significantly diminished after RXM administration”

    Animalsbleomycin-induced modellung

    Roxithromycin attenuates bleomycin-induced pulmonary fibrosis by targeting senescent cells

    Acta pharmacologica Sinica

More on Cellular senescence

Pulmonary fibrosis

downin mice1

1 study
  1. Roxithromycin decreases pulmonary fibrosis in mice (bleomycin-induced pulmonary fibrosis model).

    “RXM was shown to attenuate lung injury, inflammation, and fibrosis.”

    Animalsbleomycin-induced pulmonary fibrosis modellung

    Roxithromycin attenuates bleomycin-induced pulmonary fibrosis by targeting senescent cells

    Acta pharmacologica Sinica

More on Pulmonary fibrosis

Trial sponsors

Latest

Dec 2025: 0Jan 2026: 1Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 01 paper in 12 months